Androgen receptor inhibitor–induced “BRCAness” and PARP inhibition are synthetically lethal for castration-resistant prostate cancer

@article{Li2017AndrogenRI,
  title={Androgen receptor inhibitor–induced “BRCAness” and PARP inhibition are synthetically lethal for castration-resistant prostate cancer},
  author={Likun Li and S. Karanika and Guang Yang and Jiangxiang Wang and Sanghee Park and B. Broom and G. Manyam and W. Wu and Yong Luo and Spyridon Panagiotis Basourakos and Jian H. Song and G. Gallick and T. Karantanos and Dimitrios Korentzelos and A. Azad and Jeri Kim and P. Corn and A. Aparicio and C. Logothetis and P. Troncoso and T. Heffernan and C. Toniatti and Hyun-Sung Lee and Ju-Seog Lee and Xuemei Zuo and Wenjun Chang and Jianhua Yin and T. Thompson},
  journal={Science Signaling},
  year={2017},
  volume={10}
}
Androgen receptor inhibition induces a “BRCAness” state that may be exploited with PARP inhibitors in patients with advanced prostate cancer. Engineering BRCAness and chemotherapeutic sensitivity BRCA mutations impair a double-strand break DNA repair pathway that forces cells to use a PARP-dependent repair pathway. PARP inhibitors are selectively toxic to breast cancers with BRCA mutations, spurring the search for other tumors or ways in which to apply such exquisitely tumor-targeted therapy… Expand
PARP Inhibitors in Prostate Cancer–the Preclinical Rationale and Current Clinical Development
TLDR
An extensive overview of published and ongoing trials exploring PARP inhibitors in treatment of prostate cancer is provided and the underlying biology is discussed, suggesting a wider potential than initially thought. Expand
PARP Inhibitors in Metastatic Prostate Cancer: Evidence to Date
TLDR
Early data are promising for the combination of PARPi with second-generation antiandrogens and with immunotherapy, and the hope is that the patient population who may benefit from PARPi will continue to expand. Expand
Identification of Novel Biomarkers of Homologous Recombination Defect in DNA Repair to Predict Sensitivity of Prostate Cancer Cells to PARP-Inhibitors
TLDR
State-of-the-art potential biomarkers that could be predictive of cancer cell synthetic lethality with PARP inhibitors are reviewed to better stratify prostate cancer patients who might benefit from target therapy. Expand
Androgen Receptor Inhibitor Enhances the Antitumor Effect of PARP Inhibitor in Breast Cancer Cells by Modulating DNA Damage Response
TLDR
The study shows posttranslational regulation of NKX3.1 via TOPORS upregulation by AZD3514-induced ATM inactivation–increased olaparib sensitivity in AR-positive and TOPORS-expressing breast cancer cells, and suggests the antitumor effect of AZD 3514/olaparIB cotreatment is caused by compromised DDR activity in breast cancer cell lines and in a xenograft model. Expand
Synergism of PARP inhibitor fluzoparib (HS10160) and MET inhibitor HS10241 in breast and ovarian cancer cells.
TLDR
The results suggest that the combination of HS10241 and HS10160 may benefit patients bearing tumors overexpressing MET as well as those resistant to single-agent PARPi treatment. Expand
Response prediction biomarkers and drug combinations of PARP inhibitors in prostate cancer.
TLDR
The potential response prediction biomarkers and synergistic combinations studied in the preclinical and clinical stages are provided, which may expand the population of patients with prostate cancer who may benefit from PARP inhibitors. Expand
PARP inhibitors in prostate cancer: practical guidance for busy clinicians.
TLDR
Compared with either enzalutamide or abiraterone, olaparib demonstrated an overall survival benefit in men with metastatic castration-resistant prostate cancer who had disease progression while receiving enzalUTamide and/or abIRaterone. Expand
Changing the History of Prostate Cancer with New Targeted Therapies
TLDR
Different novel strategies to improve outcomes in patients with prostate cancer are reviewed, including drug combinations with phosphatidylinositol-3-kinase (PI3K) or protein kinase B (AKT) inhibitors, as mechanisms to overcome resistance or to induce BRCAness and synthetic lethality. Expand
Ralaniten Sensitizes Enzalutamide-Resistant Prostate Cancer to Ionizing Radiation in Prostate Cancer Cells that Express Androgen Receptor Splice Variants
TLDR
This study investigates whether blocking the transcriptional activities of full-length AR and AR-Vs with ralaniten leads to enhanced sensitivity to radiotherapy. Expand
PARP inhibitors for homologous recombination-deficient prostate cancer
TLDR
This work will discuss the treatment of castrate-resistant prostate cancer (CRPC), with a focus on the use of poly (ADP-ribose) polymerase (PARP) inhibitors in this space and evidence for use in HR-deficient patients. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 56 REFERENCES
Targeting DNA Repair: The Role of PARP Inhibition in the Treatment of Castration-Resistant Prostate Cancer
TLDR
Current evidence from a phase II clinical trial supports further testing of PARP inhibitors for the treatment of metastatic CRPC with either germline or somatic defects in BRCA2, ATM, PALB2, and other DNA repair genes. Expand
PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies.
TLDR
Accumulating evidence suggests that PARPi may have a wider application in the treatment of sporadic high-grade serous ovarian cancer, and cancers defective in DNA repair pathways, such as prostate, endometrial, and pancreatic cancers. Expand
PARP inhibitors: A new era of targeted therapy.
TLDR
The focus is to outline the emerging molecular mechanisms, preclinical evidence and clinical applications of PARP inhibitors especially in nonBRCA cancers, and review the combination strategies compatible with PARP inhibitor therapy. Expand
Targeting Poly(ADP-Ribose) Polymerase and the c-Myb–Regulated DNA Damage Response Pathway in Castration-Resistant Prostate Cancer
TLDR
New mechanism-based therapeutic approaches for PCa are revealed by targeting PARP and the DDR pathway involving c-Myb, TopBP1, ataxia telangiectasia mutated– and Rad3-related (ATR), and Chk1. Expand
Androgen receptor signaling regulates DNA repair in prostate cancers.
UNLABELLED We demonstrate that the androgen receptor (AR) regulates a transcriptional program of DNA repair genes that promotes prostate cancer radioresistance, providing a potential mechanism byExpand
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.
TLDR
Treatment with the PARP inhibitor olaparib in patients whose prostate cancers were no longer responding to standard treatments and who had defects in DNA-repair genes led to a high response rate. Expand
Poly (ADP-ribose) polymerase inhibitors: on the horizon of tailored and personalized therapies for epithelial ovarian cancer
TLDR
Clinical development of PARP inhibitors that target DNA repair defects in cancer is a novel and imperative stride in individualized identification of molecular characteristics in management of ovarian cancer. Expand
DNA damage response and prostate cancer: defects, regulation and therapeutic implications
TLDR
Specific DDR defects in prostate cancer that occur during disease progression are discussed, to summarize recent advances in understanding the regulation of DDR, and to present potential therapeutic opportunities through combinational targeting of the intact components of DDR signaling pathways. Expand
The Mutational Landscape of Lethal Castrate Resistant Prostate Cancer
TLDR
The mutational landscape of a heavily treated metastatic cancer is described, novel mechanisms of AR signalling deregulated in prostate cancer are identified, and candidates for future study are prioritize. Expand
The convergence of DNA damage checkpoint pathways and androgen receptor signaling in prostate cancer.
TLDR
This review will focus on the connections between checkpoint signaling and the AR in PCa and describes what is known about how components of checkpoint signaling regulate AR activity and what questions still face the field. Expand
...
1
2
3
4
5
...